C4 Therapeutics, Inc. Additional Paid in Capital, Common Stock
C4 Therapeutics, Inc. (CCCC) had Additional Paid in Capital, Common Stock of $1.04 billion as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-11
- 2026-06-30: Additional Paid in Capital, Common Stock $1.04B.
- 2026-03-31: Additional Paid in Capital, Common Stock $998.38M.
- 2025-12-31: Additional Paid in Capital, Common Stock $995.22M.
- 2025-09-30: Additional Paid in Capital, Common Stock $872.52M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $1.04B 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $998.38M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $995.22M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $872.52M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $860.13M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $855.11M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $849.63M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $841.32M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $821.95M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $815.40M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $774.62M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $710.55M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $702.07M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $695.61M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $689.26M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $682.29M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $675.92M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $667.51M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $658.09M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $650.99M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $643.87M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $468.59M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $464.60M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $6.09M 10-Q · filed 2020-11-12 | |
| 2019-12-31 | $5.53M 10-K · filed 2021-03-11 | $5.52M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |